Medical device companies presented new data this week at the Advanced Technologies & Treatments for Diabetes conference.

Tandem Diabetes Care announced today that it launched its next-generation Control-IQ+ automated insulin delivery algorithm in ...

Tandem Diabetes Care (Nasdaq:TNDM) today announced positive data supporting its automated insulin delivery technology for ...

The use of an automated insulin delivery (AID) system reduced A1c and hyperglycemia without increasing hypoglycemia in people ...

Control-IQ+ builds on the existing features of Tandem’s industry-leading Control-IQ algorithm, which in addition to adjusting ...

system can pull data from glucose monitors and integrate with Tandem’s insulin pumps, automatically calculating how much basal insulin patients should receive. The expanded indication increases ...

Control-IQ+, compatible with both the t:slim X2 insulin pump and Tandem Mobi System, is now available for people with type 1 diabetes ages 2 years and older and adults with type 2 diabetes.

Adults with insulin-treated type 2 diabetes had greater HbA1c reductions and larger improvement in time in range with use of ...

Tandem Diabetes (TNDM) announced the United States commercial launch of Control-IQ+ technology, the latest generation of the company’s advanced ...

Amsterdam played host to this year's edition of the International Conference on Advanced Technologies & Treatments for ...

Tandem Diabetes shares crashed Thursday after the insulin pump-maker issued light sales guidance for 2025. For the year, the company expects $997 million to $1.007 billion in sales. The high end ...